Detalhe da pesquisa
1.
Sequence not salvage.
Br J Haematol
; 204(5): 1590-1592, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38563345
2.
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.
Haematologica
; 109(3): 777-786, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37731379
3.
Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN.
Am J Hematol
; 2024 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38622840
4.
Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes.
Hum Mol Genet
; 30(12): 1142-1153, 2021 06 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33751038
5.
Time-to-event surrogate end-points in multiple myeloma randomised trials from 2005 to 2019: A surrogacy analysis.
Br J Haematol
; 200(5): 587-594, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495317
6.
Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma: U.S. Myeloma Immunotherapy Consortium real world experience.
Haematologica
; 2023 10 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855036
7.
Impact of academic medical center access on outcomes in multiple myeloma.
Am J Hematol
; 98(1): 41-48, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36266759
8.
A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma.
Future Oncol
; 19(1): 7-17, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36779512
9.
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Br J Haematol
; 199(3): 355-365, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36111391
10.
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood
; 136(8): 936-945, 2020 08 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325490
11.
Optimizing Thromboembolism Prophylaxis for the Contemporary Age of Multiple Myeloma.
J Natl Compr Canc Netw
; 20(1): 91-95, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34991076
12.
Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma.
Eur J Haematol
; 109(5): 559-565, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36054450
13.
A Phase 1 dose-escalation study of disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker.
BMC Cancer
; 21(1): 510, 2021 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33957901
14.
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance.
Am J Hematol
; 96(7): 846-853, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33709474
15.
XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant.
Mol Carcinog
; 58(12): 2327-2339, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31544312
16.
Polymorphism in ANRIL is associated with relapse in patients with multiple myeloma after autologous stem cell transplant.
Mol Carcinog
; 56(7): 1722-1732, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28150872
17.
Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma.
Br J Haematol
; 171(1): 74-83, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26058589
18.
Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group.
Front Health Serv
; 4: 1354760, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38721434
19.
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy.
Blood Adv
; 8(1): 251-259, 2024 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37855718
20.
Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk.
Blood Cancer J
; 14(1): 69, 2024 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38649340